Highlights:

  • Starting April 1st, Company’s virtual consultation service gives patients access to clinic services and doctors trained to prescribe medical cannabis
  • Teleconsultation service anticipated to quickly expand to meet potential growing demand for telehealth services, including Company’s 120,000 patients from its ILANS and Zerenia clinics
  • Khiron has already received initial approvals from third party payers to include teleconsultation services in its insured service offerings
  • Khiron and its clinics continue to be operational during COVID-19 pandemic under an exemption decreed by the Government of Colombia, without any requirement for further authorization
  • Virtual medical services complement Khiron’s delivery service that is already successfully delivering prescriptions directly to patients’ homes
  • Telemedicine acceptance increasing rapidly, with average US compound visit growth of 52% per year from 2005 – 2014 (Source: JAMA)
  • Khiron is the first company authorized to sell medical cannabis in Colombia

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN, OTCQX:KHRNF, Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced the Company has launched its teleconsultation services, leveraging its medical team and existing patient network to meet essential patient needs during the current COVID-19 pandemic. From an initial beta launch, the Company anticipates rapidly expanding services across its entire patient network amidst the growing acceptance of telemedicine services.


“We are in unprecedented times and so it is more important than ever for Khiron to continue to meet the medical needs of our patients. The launch of our teleconsultation services was made possible with our on-staff doctor expertise and established patient network, allowing us to move swiftly to continue to deliver clinical services and prescriptions for medical cannabis and other drugs,  directly to the patients who need it,” comments Alvaro Torres, Khiron CEO and director.

Khiron’s teleconsultation services launch on April 1st, with an initial beta phase to serve priority patient needs. Expanded services will launch in the coming weeks to be fully available to patients across Colombia, including to the Company’s over 120,000 patient network established through its ILANS and Zerenia medical facilities. The Company is working closely with third party payers to ensure the program meets their insurance coverage requirements.

“Khiron has established contingency plans in place for all our facilities, including our medical facilities which are essential to serving the community. Those plans were put into action and our medical facilities and supply chain remain operating within strict government guidelines established as a result of the current pandemic. I commend our frontline staff for their continued hard work and commitment to meeting patient needs during this difficult time,” said Mr. Torres.

Khiron is the first, and currently the only, Company authorized to sell medical cannabis in Colombia, having recently obtained certification of Good Elaboration Practices (GEP) for Magistral Preparations with Cannabis. Under Colombian regulations, GEP is a manufacturing and processing certification that is a mandatory requirement for commercializing customized medical cannabis prescriptions known as magistral preparations.

About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Latin America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The Company delivers best in class regulatory compliance, has the first approved line of CBD cosmetic products on shelf in Colombia, and is fully authorized to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis in the country.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Visit Khiron online at www.khiron.ca and on Instagram @khironlife

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN, OTC:KHRNF) for an Investor Presentation.

Source

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less

 Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States will release its fourth quarter 2020 financial results on Tuesday, March 23, 2021 before markets open. Following the earnings release, management will host a conference call at 8:30 AM Eastern Time to review the financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 7066881. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until March 30, 2021 . To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 7066881.

Keep reading... Show less